Infectious disease threats are increasingly recognized as a major contributor to mortality in wild populations of African wild dog (Lycaon pictus, AWD). Canine distemper virus (CDV) infection has been implicated as a cause of pack mortality in both captive and wild AWD populations. Ten animals were vaccinated with RecombitekTM C3, a vaccine containing a recombinant CDV, and modified live canine parvovirus (CPV) and adenovirus-2 components, at 8, 12, and 16 wk of age. Half of the pups received the vaccine IM and the other half SC. All ten pups had a positive serological response to CDV after the second vaccination, which decreased or stagnated after the third vaccination. Half of the pups had CDV titers ≥32 at 20 wk of age. Titers to CPV were high in all pups prior to vaccination and dropped precipitously over the course of the vaccine series. At the last sampling period, only 50% of the pups had measurable CPV titers. An initially higher titer was seen for CDV in the IM administration group; however, this was not significant at later time points. Vaccination with Recombitek C3 appears to be safe and effected a sustained serological response to CDV in AWD.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.